Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice

We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological & pharmaceutical bulletin 1997/06/15, Vol.20(6), pp.694-697
Hauptverfasser: OMATA, Takeshi, SEGAWA, Yoshihide, TAMAKI, Hajime, FUJISAKU, Atsushi, KOIKE, Takao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 697
container_issue 6
container_start_page 694
container_title Biological & pharmaceutical bulletin
container_volume 20
creator OMATA, Takeshi
SEGAWA, Yoshihide
TAMAKI, Hajime
FUJISAKU, Atsushi
KOIKE, Takao
description We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.
doi_str_mv 10.1248/bpb.20.694
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16081167</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16081167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</originalsourceid><addsrcrecordid>eNpdkb2PEzEUxC0EOsJBQ49kCUSBboM_dr3rMoQDIt2JAmhoLNv7ljjatYPtRaTjT8chUQoaW9b8NPOeB6HnlCwpq7u3Zm-WjCyFrB-gBeV1WzWMNg_RgkjaVYI23WP0JKUdIaQljF-hK8kok5Iv0J_vFSXkBt_-zlHbDD0eYpjw_cEGc3xHN084zwainceQXMJfCug8XoWDnjR-d4M3fuuMywnnLeD38AvGsJ_AZxwGvA7jqH-Arza-n21xX8W8jS4Xn-Jx7yw8RY8GPSZ4dr6v0bcPt1_Xn6q7zx8369VdZUXT5YpxTSgT0AttjaaawVBr0tdEUC7MQHXfCdJIwxiXwFve0L5nHdcdEQ03WvJr9Prku4_h5wwpq8klC2U8D2FOigrSUSraAr78D9yFOfoym6J1LQsi2yP15kTZGFKKMKh9dJOOB0WJOpaiSimKEVVKKfCLs-VsJugv6LmFor866zpZPQ5Re-vSBWNtWbLpCrY-YbuUy6dedB2zsyMcE2mx-5d6Okr4RbVbHRV4_hfHmasy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449167977</pqid></control><display><type>article</type><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</creator><creatorcontrib>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</creatorcontrib><description>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.20.694</identifier><identifier>PMID: 9212993</identifier><language>eng</language><publisher>Tokyo: The Pharmaceutical Society of Japan</publisher><subject>Adjuvants, Immunologic - isolation &amp; purification ; Adjuvants, Immunologic - pharmacology ; Animals ; Antibodies - blood ; Antibodies - immunology ; Antirheumatic Agents - isolation &amp; purification ; Antirheumatic Agents - pharmacology ; Arthritis, Experimental - immunology ; Arthritis, Experimental - pathology ; Arthritis, Experimental - prevention &amp; control ; Biological and medical sciences ; Collagen - immunology ; collagen-induced arthritis ; Cyclophosphamide - pharmacology ; Diseases of the osteoarticular system ; Hindlimb ; Hypersensitivity, Delayed - immunology ; Immunomodulators ; Immunosuppressive Agents - pharmacology ; Inflammatory joint diseases ; Lipids - isolation &amp; purification ; Lipids - pharmacology ; Male ; Mannans - isolation &amp; purification ; Mannans - pharmacology ; Medical sciences ; methotrexate ; Methotrexate - pharmacology ; Mice ; Mice, Inbred DBA ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - chemistry ; Pharmacology. Drug treatments ; Severity of Illness Index ; Z-100</subject><ispartof>Biological and Pharmaceutical Bulletin, 1997/06/15, Vol.20(6), pp.694-697</ispartof><rights>The Pharmaceutical Society of Japan</rights><rights>1997 INIST-CNRS</rights><rights>Copyright Japan Science and Technology Agency 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2761358$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9212993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OMATA, Takeshi</creatorcontrib><creatorcontrib>SEGAWA, Yoshihide</creatorcontrib><creatorcontrib>TAMAKI, Hajime</creatorcontrib><creatorcontrib>FUJISAKU, Atsushi</creatorcontrib><creatorcontrib>KOIKE, Takao</creatorcontrib><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</description><subject>Adjuvants, Immunologic - isolation &amp; purification</subject><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Animals</subject><subject>Antibodies - blood</subject><subject>Antibodies - immunology</subject><subject>Antirheumatic Agents - isolation &amp; purification</subject><subject>Antirheumatic Agents - pharmacology</subject><subject>Arthritis, Experimental - immunology</subject><subject>Arthritis, Experimental - pathology</subject><subject>Arthritis, Experimental - prevention &amp; control</subject><subject>Biological and medical sciences</subject><subject>Collagen - immunology</subject><subject>collagen-induced arthritis</subject><subject>Cyclophosphamide - pharmacology</subject><subject>Diseases of the osteoarticular system</subject><subject>Hindlimb</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Immunomodulators</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Inflammatory joint diseases</subject><subject>Lipids - isolation &amp; purification</subject><subject>Lipids - pharmacology</subject><subject>Male</subject><subject>Mannans - isolation &amp; purification</subject><subject>Mannans - pharmacology</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>Methotrexate - pharmacology</subject><subject>Mice</subject><subject>Mice, Inbred DBA</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - chemistry</subject><subject>Pharmacology. Drug treatments</subject><subject>Severity of Illness Index</subject><subject>Z-100</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkb2PEzEUxC0EOsJBQ49kCUSBboM_dr3rMoQDIt2JAmhoLNv7ljjatYPtRaTjT8chUQoaW9b8NPOeB6HnlCwpq7u3Zm-WjCyFrB-gBeV1WzWMNg_RgkjaVYI23WP0JKUdIaQljF-hK8kok5Iv0J_vFSXkBt_-zlHbDD0eYpjw_cEGc3xHN084zwainceQXMJfCug8XoWDnjR-d4M3fuuMywnnLeD38AvGsJ_AZxwGvA7jqH-Arza-n21xX8W8jS4Xn-Jx7yw8RY8GPSZ4dr6v0bcPt1_Xn6q7zx8369VdZUXT5YpxTSgT0AttjaaawVBr0tdEUC7MQHXfCdJIwxiXwFve0L5nHdcdEQ03WvJr9Prku4_h5wwpq8klC2U8D2FOigrSUSraAr78D9yFOfoym6J1LQsi2yP15kTZGFKKMKh9dJOOB0WJOpaiSimKEVVKKfCLs-VsJugv6LmFor866zpZPQ5Re-vSBWNtWbLpCrY-YbuUy6dedB2zsyMcE2mx-5d6Okr4RbVbHRV4_hfHmasy</recordid><startdate>19970601</startdate><enddate>19970601</enddate><creator>OMATA, Takeshi</creator><creator>SEGAWA, Yoshihide</creator><creator>TAMAKI, Hajime</creator><creator>FUJISAKU, Atsushi</creator><creator>KOIKE, Takao</creator><general>The Pharmaceutical Society of Japan</general><general>Maruzen</general><general>Japan Science and Technology Agency</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>19970601</creationdate><title>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</title><author>OMATA, Takeshi ; SEGAWA, Yoshihide ; TAMAKI, Hajime ; FUJISAKU, Atsushi ; KOIKE, Takao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c658t-23a0126ed6acba1a2ef4a0d406136bf1ad86059b2239e37351dd283a80653ba93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adjuvants, Immunologic - isolation &amp; purification</topic><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Animals</topic><topic>Antibodies - blood</topic><topic>Antibodies - immunology</topic><topic>Antirheumatic Agents - isolation &amp; purification</topic><topic>Antirheumatic Agents - pharmacology</topic><topic>Arthritis, Experimental - immunology</topic><topic>Arthritis, Experimental - pathology</topic><topic>Arthritis, Experimental - prevention &amp; control</topic><topic>Biological and medical sciences</topic><topic>Collagen - immunology</topic><topic>collagen-induced arthritis</topic><topic>Cyclophosphamide - pharmacology</topic><topic>Diseases of the osteoarticular system</topic><topic>Hindlimb</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Immunomodulators</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Inflammatory joint diseases</topic><topic>Lipids - isolation &amp; purification</topic><topic>Lipids - pharmacology</topic><topic>Male</topic><topic>Mannans - isolation &amp; purification</topic><topic>Mannans - pharmacology</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>Methotrexate - pharmacology</topic><topic>Mice</topic><topic>Mice, Inbred DBA</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - chemistry</topic><topic>Pharmacology. Drug treatments</topic><topic>Severity of Illness Index</topic><topic>Z-100</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OMATA, Takeshi</creatorcontrib><creatorcontrib>SEGAWA, Yoshihide</creatorcontrib><creatorcontrib>TAMAKI, Hajime</creatorcontrib><creatorcontrib>FUJISAKU, Atsushi</creatorcontrib><creatorcontrib>KOIKE, Takao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OMATA, Takeshi</au><au>SEGAWA, Yoshihide</au><au>TAMAKI, Hajime</au><au>FUJISAKU, Atsushi</au><au>KOIKE, Takao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>1997-06-01</date><risdate>1997</risdate><volume>20</volume><issue>6</issue><spage>694</spage><epage>697</epage><pages>694-697</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>We evaluated the effects of Z-100, extracted from human type Mycobacterium tuberculosis strain Aoyama B, on collagen-induced arthritis (CIA) in mice. One hundred thirty-five DBA-1K mice, 8 weeks of age, were assigned to 9 groups and immunized with bovine type II collagen (CII) or CFA. From the next day, Z-100 at does of 0.004, 0.04 or 0.4 mg/kg B.W./d for 48 d was intradermally injected into the tail base. Methotrexate (MTX) at daily doses of 0.1, 0.3, or 1.0 mg/kg B.W. and cyclophosphamide (CY) and at a daily dose of 5 mg/kg. B.W. were used as reference drugs. The effects of these drugs on CIA mice were evaluated in terms of the incidence of CIA, the arthritis index (AI), and hind paw edema, after which the animals were sacrificed at 49 d, and both anti-CII antibody titer and delayed-type hypersensitivity (DTH) reaction were measured. In the arthritic control groups, the AI and hind paw edema were significantly increased after the second immunization on day 28. The anti-CII antibody titer and DTH reaction were significantly increased compared to normal mice on day 49. Z-100 significantly inhibited the AI at a dose of 0.4 mg/kg/d on day 49, and suppressed the incidence of both CIA and hind paw edema. Increases in both anti-CII antibody titer and DTH reaction in CIA mice were prevented by treatment with Z-100 at 0.4 mg/kg/d. MTX, in a dose-dependent manner, and CY, at a dose of 5 mg/kg/d, inhibited the incidence of CIA, AI hind paw edema, anti-CII antibody titer and DTH reaction in CIA mice. Z-100 at a dose of 0.4 mg/kg was as effective as MTX was at a dose of 0.3 mg/kg against the DTH reaction, and it had no side effects. These results suggest the usefulness of Z-100 in patients with chronic rheumatoid arthritis.</abstract><cop>Tokyo</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>9212993</pmid><doi>10.1248/bpb.20.694</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 1997/06/15, Vol.20(6), pp.694-697
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_16081167
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry
subjects Adjuvants, Immunologic - isolation & purification
Adjuvants, Immunologic - pharmacology
Animals
Antibodies - blood
Antibodies - immunology
Antirheumatic Agents - isolation & purification
Antirheumatic Agents - pharmacology
Arthritis, Experimental - immunology
Arthritis, Experimental - pathology
Arthritis, Experimental - prevention & control
Biological and medical sciences
Collagen - immunology
collagen-induced arthritis
Cyclophosphamide - pharmacology
Diseases of the osteoarticular system
Hindlimb
Hypersensitivity, Delayed - immunology
Immunomodulators
Immunosuppressive Agents - pharmacology
Inflammatory joint diseases
Lipids - isolation & purification
Lipids - pharmacology
Male
Mannans - isolation & purification
Mannans - pharmacology
Medical sciences
methotrexate
Methotrexate - pharmacology
Mice
Mice, Inbred DBA
Mycobacterium tuberculosis
Mycobacterium tuberculosis - chemistry
Pharmacology. Drug treatments
Severity of Illness Index
Z-100
title Z-100, Extracted from Mycobacterium tuberculosis Strain Aoyama B, Inhibits the Development of Collagen-Induced Arthritis in Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A03%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Z-100,%20Extracted%20from%20Mycobacterium%20tuberculosis%20Strain%20Aoyama%20B,%20Inhibits%20the%20Development%20of%20Collagen-Induced%20Arthritis%20in%20Mice&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=OMATA,%20Takeshi&rft.date=1997-06-01&rft.volume=20&rft.issue=6&rft.spage=694&rft.epage=697&rft.pages=694-697&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.20.694&rft_dat=%3Cproquest_cross%3E16081167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449167977&rft_id=info:pmid/9212993&rfr_iscdi=true